DLBCL Infopoint 2025

Dear colleagues!
our Insights in DLBCL: New Horizons 2025 meeting was a great success with superb scientific lectures and fruitful discussions, giving insights in different therapeutic approaches across Europe and the U.S. Thank you to all speakers and participants for making this happen.
And of course a special thank you goes out to our sponsors who have made this meeting possible.
This said, we are looking forward to welcoming you again at Insights in DLBCL: New Horizons 2026!

Pre-register now for 2026!

Best regards
Johannes Düll
Senior physician
Universitätsklinik Würzburg

Welcome and introduction
Dr. med. Johannes Düll

Methods to confirm success in DLBCL: PET and ctDNA – are we already there where we want?
Dr. Jason R. Westin

CNS Lymphoma – Diagnostic and treatment – state of the art
Professor Andrés J. M. Ferreri, MD

Radiotherapy in DLBCL –
from bridge to CAR-T to consolidation
Dr. med. Michael Oertel

Immunotherapy in DLBCL long term results- efficacy and toxicities
Prof. Dr. med. Max Topp

CAR-T in second line with focus on bridge to CAR-T concepts
Prof. Dr. med. Björn Chapuy

Bispecs: mono vs. combinations: what can we expect?
Professor Pieternella Lugtenburg, MD, PhD

Case studies (2nd/3rd line) with focus on treatment decision and sequencing of therapies
Florian Eisele, MD

What‘s hot and what‘s not? DLBCL-specific highlights of ASH 2024
Dr. med. Johannes Düll

Conclusion and Farewell

Dieses Bild hat ein leeres Alt-Attribut. Der Dateiname ist Sponsoren.png

Melden Sie sich jetzt für unseren Newsletter an